JP2005516997A5 - - Google Patents

Download PDF

Info

Publication number
JP2005516997A5
JP2005516997A5 JP2003565505A JP2003565505A JP2005516997A5 JP 2005516997 A5 JP2005516997 A5 JP 2005516997A5 JP 2003565505 A JP2003565505 A JP 2003565505A JP 2003565505 A JP2003565505 A JP 2003565505A JP 2005516997 A5 JP2005516997 A5 JP 2005516997A5
Authority
JP
Japan
Prior art keywords
mgf
use according
polypeptide
sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003565505A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005516997A (ja
Filing date
Publication date
Priority claimed from GBGB0202906.4A external-priority patent/GB0202906D0/en
Application filed filed Critical
Publication of JP2005516997A publication Critical patent/JP2005516997A/ja
Publication of JP2005516997A5 publication Critical patent/JP2005516997A5/ja
Pending legal-status Critical Current

Links

JP2003565505A 2002-02-07 2003-02-06 心筋損傷の阻止のためのインスリン様増殖因子iスプライス変異体の使用 Pending JP2005516997A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0202906.4A GB0202906D0 (en) 2002-02-07 2002-02-07 Prevention of myocardial damage
PCT/GB2003/000537 WO2003066082A1 (en) 2002-02-07 2003-02-06 Use of the insulin-like-growth factor i splice variant mgf for the prevention of myocardial damage

Publications (2)

Publication Number Publication Date
JP2005516997A JP2005516997A (ja) 2005-06-09
JP2005516997A5 true JP2005516997A5 (cg-RX-API-DMAC7.html) 2006-10-19

Family

ID=9930632

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003565505A Pending JP2005516997A (ja) 2002-02-07 2003-02-06 心筋損傷の阻止のためのインスリン様増殖因子iスプライス変異体の使用

Country Status (9)

Country Link
US (4) US20050048028A1 (cg-RX-API-DMAC7.html)
EP (1) EP1480669B1 (cg-RX-API-DMAC7.html)
JP (1) JP2005516997A (cg-RX-API-DMAC7.html)
AU (1) AU2003244511A1 (cg-RX-API-DMAC7.html)
DK (1) DK1480669T3 (cg-RX-API-DMAC7.html)
ES (1) ES2432082T3 (cg-RX-API-DMAC7.html)
GB (1) GB0202906D0 (cg-RX-API-DMAC7.html)
PT (1) PT1480669E (cg-RX-API-DMAC7.html)
WO (1) WO2003066082A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0202906D0 (en) 2002-02-07 2002-03-27 Univ London Prevention of myocardial damage
WO2006097682A1 (en) * 2005-03-18 2006-09-21 Ucl Business Plc Mechano growth factor peptides and their use
CA2601227A1 (en) * 2005-03-18 2006-09-21 Ucl Business Plc Mecano growth factor peptides and their use
CL2007001614A1 (es) 2006-06-09 2008-08-08 Novartis Ag Polipeptido que comprende una proteina del precursor del factor de crecimiento tipo insulina, igf-1 humana, en la cual la escision del peptido e mediante una proteasa se reduce a traves de la modificacion de la proteina del precursor; y su uso para t
WO2009012443A1 (en) * 2007-07-18 2009-01-22 The Board Of Trustees Of The University Of Illinois Nanoparticles for the elution of growth factors for recovery and regeneration of organs
CN101891812B (zh) * 2010-07-09 2012-10-17 山西大学 力生长因子多肽及其制备方法和用途
CN103031277B (zh) * 2011-09-29 2015-07-15 重庆大学 力生长因子在制备无血清培养耐受型哺乳动物工程细胞中的应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460147C2 (de) 1974-12-19 1983-05-05 Ibm Deutschland Gmbh, 7000 Stuttgart Anordnung zur Dekomprimierung komprimierter Information für aus schwarzen und weißen Bereichen zusammengesetze darzustellende Zeichen
US4732863A (en) 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
US4963665A (en) 1986-01-07 1990-10-16 Washington University Human preproinsulin-like growth factor I
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
SE8703625D0 (sv) * 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5652214A (en) * 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
DK0437563T3 (da) 1989-08-07 1995-05-29 Debio Rech Pharma Sa Bioligiske aktive lægemiddelpolymerderivater
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
SE9100099D0 (sv) 1991-01-11 1991-01-11 Kabi Pharmacia Ab Use of growth factor
SE9101341D0 (sv) 1991-05-03 1991-05-03 Kabi Pharmacia Ab New medicinal use
ES2101865T3 (es) * 1991-08-01 1997-07-16 Genentech Inc Igf-1 para mejorar el estado neural.
US5861373A (en) * 1991-08-01 1999-01-19 Genentech, Inc IGF-1 to improve the neural condition
US5298422A (en) 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
CA2123685C (en) 1991-11-25 2003-10-07 Hans-Arne Hansson Medicament for promoting growth of mammalian nerve
FR2687681B1 (fr) * 1992-02-20 1995-10-13 Transgene Sa Conjugues polyethyleneglycol-hirudine, leur procede de preparation et leur emploi pour le traitement des thromboses.
US5840900A (en) * 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
WO1995013290A1 (en) 1993-11-12 1995-05-18 North Shore University Hospital Research Corporation Method of treating muscular dystrophy
US5730990A (en) * 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US5650496A (en) * 1995-04-14 1997-07-22 Cephalon, Inc. IGF-I purification process
GB9605124D0 (en) * 1996-03-11 1996-05-08 Royal Free Hosp School Med Method of treating muscular disorders
US6214966B1 (en) * 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
PT1075282E (pt) 1998-04-28 2005-09-30 Applied Research Systems Conjugados analogos de peg-lhrh
GB9926968D0 (en) 1999-11-15 2000-01-12 Univ London Treatment of neurological disorders
GB0011278D0 (en) * 2000-05-10 2000-06-28 Univ London Repair of nerve damage
GB0202906D0 (en) 2002-02-07 2002-03-27 Univ London Prevention of myocardial damage
GB0203552D0 (en) 2002-02-14 2002-04-03 Beaumont Nicholas J Peptide growth factor
WO2006097682A1 (en) 2005-03-18 2006-09-21 Ucl Business Plc Mechano growth factor peptides and their use

Similar Documents

Publication Publication Date Title
Pittas et al. The role of calcium handling mechanisms in reperfusion injury
JP2005505286A5 (cg-RX-API-DMAC7.html)
US20110059885A1 (en) Treatment of diseases and conditions mediated by eicosanoids
Graham et al. Helical antifreeze proteins have independently evolved in fishes on four occasions
JP2020500162A5 (cg-RX-API-DMAC7.html)
NZ603348A (en) Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
JP2006518372A5 (cg-RX-API-DMAC7.html)
JP2006521826A5 (cg-RX-API-DMAC7.html)
JP2020518268A5 (cg-RX-API-DMAC7.html)
EP0425482A1 (en) HUMAN INSULINALAGE AND PREPARATIONS THEREOF.
JP2010189394A5 (cg-RX-API-DMAC7.html)
JP2021536250A5 (cg-RX-API-DMAC7.html)
CN113429455B (zh) 用于疾病治疗的方法
WO2012014214A2 (en) Peptides derived from plasminogen activator inhibitor-1 (pai-1) for the treatment of hypertension
JP2012530060A5 (cg-RX-API-DMAC7.html)
JP2020172505A5 (cg-RX-API-DMAC7.html)
JP2011509093A5 (cg-RX-API-DMAC7.html)
JP2019521692A5 (cg-RX-API-DMAC7.html)
PT2393831T (pt) Omci modificado como inibidor do complemento
EP0596969A1 (en) Igf-ii analogues
Ohno et al. The grammatical rule for all DNA: junk and coding sequences
EP1688498A4 (en) RECOMBINANT PROTEIN WITH CANCER SUPPRESSIVE EFFECT, ITS CODING GENE AND ITS USE
JP2003334088A5 (cg-RX-API-DMAC7.html)
JP2002539829A5 (cg-RX-API-DMAC7.html)
JP2005502339A5 (cg-RX-API-DMAC7.html)